Evidence map›Paper›PMID 37975485›Full record

ArticlePediatric pulmonology2024

Prostaglandin-E1 infusion in persistent pulmonary hypertension of the newborn.

Stephanie M Tsoi, Hythem Nawaytou, Hassan Almeneisi, Martina Steurer, Yili Zhao, Jeffrey R Fineman, Roberta L Keller

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Pulmonary hypertension and acute hypoxic respiratory failure in preterm neonates.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Stephanie M TsoiDepartment of Pediatrics, Division of Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-0115-5843
Hythem NawaytouDepartment of Pediatrics, Division of Cardiology, University of California San Francisco, San Francisco, California, USA.
Hassan AlmeneisiDepartment of Pediatrics, Division of Cardiology, University of California San Francisco, San Francisco, California, USA.
Martina SteurerDepartment of Pediatrics, Division of Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.
Yili ZhaoDepartment of Pediatrics, Division of Cardiology, University of California San Francisco, San Francisco, California, USA.
Jeffrey R FinemanDepartment of Pediatrics, Division of Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.
Roberta L KellerDepartment of Pediatrics, Division of Neonatology, University of California San Francisco, San Francisco, California, USA.
University of California, San Francisco · US

Funding

TGF-ß-SOX18-Collagen metabolism in pulmonary vascular disease associated with CHDP01HL146369 · NHLBI · UNIVERSITY OF ARIZONA · PI Stephen M Black · 2020 to 2026
$18.7M
Multidisciplinary Research Training in Pediatric Pulmonary Vascular DiseaseT32HL160508 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven Herbert Abman, Eric Douglas Austin · 2022 to 2026
$1.7M
NHLBI NIH HHS P01 HL146369NHLBI NIH HHS T32 HL160508NIH HHS
6 · The paper itself

Abstract

backgroundNeonates with persistent pulmonary hypertension of the newborn (PPHN) can present with hypoxia and right ventricular dysfunction with resultant inadequate oxygen delivery and end-organ damage. This study describes the use of prostaglandin-E1 (PGE) for ductal patency to preserve right ventricular systolic function and limit afterload in newborns with PPHN.

methodsThis is a retrospective cohort study that follows the hemodynamics, markers of end-organ perfusion, length of therapeutics, and echocardiographic variables of 57 newborns who used prostglandin-E1 in the setting of PPHN.

resultsTachycardia, lactic acidosis, and supplemental oxygen use improved following PGE initiation. Fractional area change (FAC), to assess right ventricular systolic function, and pulmonary arterial acceleration time indexed to right ventricular ejection time (PAAT/RVET), to assess right ventricular afterload, also improved over three time points relative to PGE use (before, during, and after).

conclusionsOverall, we described the safety and utility of PGE in newborns with severe PPHN for stabilization while allowing natural disease progression.

Indexed as

Hypertension, PulmonaryPersistent Fetal Circulation SyndromeHumansInfant, NewbornOxygenProstaglandinsRetrospective StudiesOxygenProstaglandinsechocardiographyhypoxic respiratory failurepulmonary vascular resistancepulmonary vasodilator

Identifiers

PMID37975485
PMCPMC10872594
OpenAlexW4388783347

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.